Christopher J. Sayed, MD, anticipates exciting advancements in hidradenitis suppurativa (HS) at the 2025 American Academy of Dermatology Annual Meeting. With numerous ongoing phase 2 and phase 3 trials, the meeting will offer valuable insights into emerging therapies, including IL-17 inhibitors, JAK inhibitors, and other novel biologics and small-molecule inhibitors.
Sessions will also explore special populations (such as patients with comorbidities) and office-based procedures utilizing laser surgical deroofing, providing both experienced and newer dermatologists with practical guidance on HS management. Additionally, discussions on HS genetics and inflammatory processes will highlight significant scientific progress and future research directions.
